Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailIn-Situ Nitroxide-Mediated Radical Polymerization (Nmp) Processes: Their Understanding and Optimization
Sciannamea, Valérie; Jérôme, Robert ULg; Detrembleur, Christophe ULg

in Chemical Reviews (2008), 108(3), 1104-26

Detailed reference viewed: 42 (3 ULg)
Peer Reviewed
See detailAn in-situ NMR analysis of the formation of P- and SiO2-doped TiO2 xerogels
Bodson, Céline ULg; Lambert, Stéphanie ULg; Cattoën, Xavier et al

Poster (2010, July)

Detailed reference viewed: 15 (7 ULg)
Full Text
See detailIn-situ polymerization of monoethylenically unsaturated monomers with oligomeric or polymeric secondary amines
Detrembleur, Christophe ULg; Rüdiger, Claus; Meyer, Rolf-Volker

Patent (2004)

PROBLEM TO BE SOLVED: To provide a process for preparing a (co)oligomer or a (co)polymer. ; SOLUTION: The process for preparing a (co)oligomer or (co)polymer comprises forming a mixture containing a ... [more ▼]

PROBLEM TO BE SOLVED: To provide a process for preparing a (co)oligomer or a (co)polymer. ; SOLUTION: The process for preparing a (co)oligomer or (co)polymer comprises forming a mixture containing a monoethylencally unsaturated monomer of formula (M): HR<SP>1</SP>C=CR<SP>2</SP>R<SP>3</SP>, an oxidizing agent, at least one polymer or oligomer of formula (I), and an optional radical initiator and heating the mixture at 0-220[deg.]C. [less ▲]

Detailed reference viewed: 8 (2 ULg)
Full Text
See detailThe in-situ polymerization of monoethylenically unsaturated monomers with oligomeric or polymeric secondary amines
Detrembleur, Christophe ULg; Rüdiger, Claus; Meyer, Rolf-Volker

Patent (2004)

The present invention relates to a new process for the preparation of well-defined random and block polymers or copolymers using hindered secondary amine-oligomers or polymers.

Detailed reference viewed: 6 (2 ULg)
Full Text
See detailIn-situ polymerization of monoethylenically unsaturated monomers with secondary amines
Detrembleur, Christophe ULg; Gross, Thomas; Meyer, Rolf-Volker

Patent (2004)

PROBLEM TO BE SOLVED: To provide a novel process for producing a homopolymer, a random copolymer, or a block copolymer having a controlled molecular weight, a narrow molecular weight distribution, a high ... [more ▼]

PROBLEM TO BE SOLVED: To provide a novel process for producing a homopolymer, a random copolymer, or a block copolymer having a controlled molecular weight, a narrow molecular weight distribution, a high monomer conversion ratio, and a controlled structure. ; SOLUTION: The polymer having a controlled molecular weight, a narrow polydispersibility, a high monomer conversion ratio, and a controlled structure is produced by polymerizing a vinyl monomer during the formation of a mixture of a hindered secondary amine and an oxidizing agent at a relatively low temperature in a short reaction time. It is unnecessary to add a free radical initiator before polymerization. Further, it is unnecessary to preliminarily react the secondary amine with the oxidizing agent before adding the monomer. [less ▲]

Detailed reference viewed: 9 (2 ULg)
Full Text
See detailIn-situ polymerization of monoethylenically unsaturated monomers with secondary amines
Detrembleur, Christophe ULg; Gross, Thomas; Meyer, Rolf-Volker

Patent (2004)

A process for the preparation of any of well-defined homopolymers, random and block copolymers is disclosed. The process that entails forming a mixture of monomers, a hindered secondary amine and an ... [more ▼]

A process for the preparation of any of well-defined homopolymers, random and block copolymers is disclosed. The process that entails forming a mixture of monomers, a hindered secondary amine and an oxidizing agent is characterized in the absence of any additional free-radical initiator. [less ▲]

Detailed reference viewed: 4 (2 ULg)
Full Text
See detailIn-situ polymerization of monoethylenically unsaturated monomers with secondary amines
Detrembleur, Christophe ULg; Gross, Thomas; Meyer, Rolf-Volker

Patent (2004)

A process for the preparation of any of well-defined homopolymers, random and block copolymers is disclosed. The process that entails forming a mixture of monomers, a hindered secondary amine and an ... [more ▼]

A process for the preparation of any of well-defined homopolymers, random and block copolymers is disclosed. The process that entails forming a mixture of monomers, a hindered secondary amine and an oxidizing agent is characterized in the absence of any additional free-radical initiator. [less ▲]

Detailed reference viewed: 4 (2 ULg)
Full Text
See detailIn-situ polymerization of monoethylenically unsaturated monomers with secondary amines
Detrembleur, Christophe ULg; Gross, Thomas; Meyer, Rolf-Volker

Patent (2004)

The present invention relates to a new process for the preparation of well-defined homopolymers, random and block copolymers using a mixture of a hindered secondary amine and an oxidizing agent, without ... [more ▼]

The present invention relates to a new process for the preparation of well-defined homopolymers, random and block copolymers using a mixture of a hindered secondary amine and an oxidizing agent, without any additional free-radical initiator. [less ▲]

Detailed reference viewed: 8 (2 ULg)
Full Text
See detailIn-situ polymerization of monoethylenically unsaturated monomers with secondary amines
Meyer, Rolf-Volker; Gross, Thomas; Detrembleur, Christophe ULg

Patent (2004)

The present invention relates to a new process for the preparation of well-defined homopolymers, random and block copolymers using a mixture of a hindered secondary amine and an oxidizing agent, without ... [more ▼]

The present invention relates to a new process for the preparation of well-defined homopolymers, random and block copolymers using a mixture of a hindered secondary amine and an oxidizing agent, without any additional free-radical initiator. [less ▲]

Detailed reference viewed: 25 (9 ULg)
Peer Reviewed
See detailIn-situ SAXS of resorcinol-formaldehyde gel formation: either colloid aggregation or microphase separation
Gommes, Cédric ULg; Roberts, Anthony; Goderis, Bart

Poster (2008, October)

Detailed reference viewed: 2 (0 ULg)
Full Text
Peer Reviewed
See detailIn-Source Decay during Matrix-Assisted Laser Desorption/Ionization Combined with the Collisional Process in an FTICR Mass Spectrometer
Asakawa, Daiki; Calligaris, David; Zimmerman, Tyler et al

in Analytical Chemistry (2013), 85

The type of ions detected after in-source decay (ISD) in a MALDI source differs according to the ion source pressure and on the mass analyzer used. We present the mechanism leading to the final ISD ions ... [more ▼]

The type of ions detected after in-source decay (ISD) in a MALDI source differs according to the ion source pressure and on the mass analyzer used. We present the mechanism leading to the final ISD ions for a Fourier transform-ion cyclotron resonance mass spectrometer (FTICR MS). The MALDI ion source was operated at intermediate pressure to cool the resulting ions and increase their lifetime during the long residence times in the FTICR ion optics. This condition produces not only c′, z′, and w fragments, but also a, y′, and d fragments. In particular, d ions help to identify isobaric amino acid residues present near the Nterminal amino acid. Desorbed ions collide with background gas during desorption, leading to proton mobilization from Arg residues to a less favored protonation site. As a result, in the case of ISD with MALDI FTICR, the influence of the Arg residue in ISD fragmentation is less straightforward than for TOF MS and the sequence coverage is thus improved. MALDI-ISD combined with FTICR MS appears to be a useful method for sequencing of peptides and proteins including discrimination of isobaric amino acid residues and site determination of phosphorylation. Additionally we also used new software for in silico elimination of MALDI matrix peaks from MALDI-ISD FTICR mass spectra. The combination of high resolving power of an FTICR analyzer and matrix subtraction software helps to interpret the low m/z region of MALDI-ISD spectra. Finally, several of these developed methods are applied in unison toward a MALDI ISD FTICR imaging experiment on mouse brain to achieve better results. [less ▲]

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailThe in-vitro antimicrobial activity of some medicinal plants against beta-lactam-resistant bacteria
Gangoue Pieboji, Joseph ULg; Eze, N.; Ngongang Djintchui, A. et al

in J Infect Dev Ctries (2009), 3(9), 671-80

BACKGROUND: In effort to identify novel bacterial agents, this study was initiated to evaluate the antimicrobial properties of 17 crude extracts from 12 medicinal plants against beta-lactam-resistant ... [more ▼]

BACKGROUND: In effort to identify novel bacterial agents, this study was initiated to evaluate the antimicrobial properties of 17 crude extracts from 12 medicinal plants against beta-lactam-resistant bacteria. METHODOLOGY: The antimicrobial activities of plant extracts were evaluated against clinically proved beta-lactam-resistant bacteria (Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Serratia marcescens, Acinetobacter baumannii, Staphylococcus aureus and Enterococcus sp.) and reference strains of bacteria (Escherichia coli ATCC 35218, Enterobacter aerogenes ATCC 29751, E. aerogenes ATCC 13048, Pseudomonas aeruginosa ATCC 27853 and Enterococcus hirae ATCC 9790) by using disc-diffusion and agar-dilution assays. RESULTS: The crude plant extracts demonstrated broad spectrum activity against all bacteria tested with inhibition zones in the range of 8-30 mm. The minimal inhibitory concentration (MIC) values of different plant extracts against the tested bacteria were found to range from <or= 0.3 to >or= 10 mg ml(-1). The most active plant extracts were from Dortenia picta and Bridelia micrantha (MIC: 1.25-10 mg ml(-1)) on beta-lactam-resistant Gram-negative bacilli and the extracts from B. micrantha, Mallotus oppositifolius, Garcinia lucida, Garcinia. kola, Campylospermum densiflorum (leaves) and C. zenkeri (root) on beta-lactam-resistant Gram-positive cocci (MIC: <or= 0.3-5 mg ml(-1)). CONCLUSION: Of the 17 plant extracts studied, seven showed good antimicrobial activity against the tested bacteria. The stem bark of B. micrantha and the leaves of D. picta were most active towards beta-lactamase producing Gram-negative bacilli. This study shows that medicinal plants could be sources of compounds which can be used to fight against beta-lactam resistant bacteria. [less ▲]

Detailed reference viewed: 71 (7 ULg)
Full Text
Peer Reviewed
See detailIn-Vitro Differences among Nonsteroidal Antiinflammatory Drugs in Their Activities Related to Osteoarthritis Pathophysiology
Henroitin, Y.; Reginster, Jean-Yves ULg

in Osteoarthritis and Cartilage (1999), 7(3), 355-7

Detailed reference viewed: 15 (1 ULg)
Peer Reviewed
See detailIN-VITRO EVALUATION OF A-5021 ANTI-VIRAL ACTIVITY AGAINST TESTUDINID HERPESVIRUS 3 AND INITIAL PHARMACOKINETIC STUDY IN HERMANN'S TORTOISE (Testudo hermanni)
Gandar, Frederic ULg; Vrancken, Robert; Diez, Marianne ULg et al

Conference (2013, April 23)

Testudinid herpesvirus infections in tortoises belonging to the Testudinidae family are well known for decades, but their pathogenesis remains poorly understood and treatments are often empirical. This ... [more ▼]

Testudinid herpesvirus infections in tortoises belonging to the Testudinidae family are well known for decades, but their pathogenesis remains poorly understood and treatments are often empirical. This study describes the in vitro evaluation of selected anti-herpesvirus compounds against Testudinid Herpesvirus 3 (THV-3). A-5021, a compound with known broad-spectrum anti-herpetic activity, showed to be 9 times more potent than acyclovir, with an EC50 of 13.2 µM and inducing a complete inhibition of viral replication at 37.7 µM. Initial pharmacokinetic parameters were determined after a single sub-cutaneous administration of 5 and 10 mg/kg in Hermann’s tortoises (Testudo hermanni, n=3). Blood samples were collected at different time points and plasma concentrations of A-5021 were determined. No adverse effects were clinically observed and plasma concentrations remained above the EC50 for 2.8 and 4.2 h after administration of 5 and 10 mg/kg, respectively. These preliminary data provide a basis for further proof-of-concept studies for a potential prophylactic or therapeutic treatment of THV-3 infection in tortoises [less ▲]

Detailed reference viewed: 86 (15 ULg)
Full Text
Peer Reviewed
See detailIn-vitro evaluation of drugs proposed as chondroprotective agents.
Bassleer, C.; Henrotin, Yves ULg; Franchimont, P.

in International Journal of Tissue Reactions (1992), 14(5), 231-41

Three proposed chondroprotective agents (CP), namely glucosamine sulfate (GAS), chondroitin sulfate (CS) and glycosaminoglycan-peptide complex (GP-C), were tested on differentiated human articular ... [more ▼]

Three proposed chondroprotective agents (CP), namely glucosamine sulfate (GAS), chondroitin sulfate (CS) and glycosaminoglycan-peptide complex (GP-C), were tested on differentiated human articular chondrocytes cultured in clusters. Chondrocyte productions of proteoglycans (PG), type II collagen (coll. II) and prostaglandin E2 (PGE2) were established by specific radioimmunoassays applied to the culture medium (CM) and in chondrocyte clusters (CC). Collagenolytic activity was assayed in CM. DNA synthesis, studied by measuring 3H-thymidine incorporation, was unaffected by CS and GAS. GP-C, at low concentration, stimulated DNA synthesis. GP-C, at higher doses, induced a high increase in PG and coll. II productions. GAS and CS induced a stimulatory effect limited to PG production. None of the CP tested here affected the basal PGE2 production by human chondrocytes. [less ▲]

Detailed reference viewed: 15 (0 ULg)
Full Text
Peer Reviewed
See detailIn-vivo studies on Haemaccel-fibronectin interaction in man.
Damas, Pierre ULg; Adam, Aurore ULg; Buret, J. et al

in European Journal of Clinical Investigation (1987), 17(2), 166-73

An enzyme-linked immunoassay has been recently set up for direct measurement of the binding capacity of plasma fibronectin to gelatin. This binding capacity could be completely inhibited in vitro by an ... [more ▼]

An enzyme-linked immunoassay has been recently set up for direct measurement of the binding capacity of plasma fibronectin to gelatin. This binding capacity could be completely inhibited in vitro by an eight-fold excess of gelatin, of Haemaccel, but not of Geloplasma. On the contrary, the levels of immunoreactive fibronectin measured by laser nephelometry did not change, in presence of 10 to 1000 micrograms ml-1 of gelatin, of Haemaccel or of Geloplasma. When infused into normal volunteers, Haemaccel provoked a strong and immediate inhibition of the plasma fibronectin binding capacity to gelatin. This inhibition was dose-dependent and maximal after infusion of 500 ml of Haemaccel. Twenty-four hours after this infusion, there was a progressive recovery of the gelatin-binding capacity, which was almost completely achieved 96 h later. The formation of complexes between Haemaccel and fibronectin was demonstrated by gel filtration chromatography and by affinity chromatography. Immunoreactive plasma fibronectin levels remained unchanged up to 24 h after infusion of 500 ml of Haemaccel. A transient decline to 50% of its initial value then occurred the second day after the infusion. Therefore, a delay existed between the formation of fibronectin-Haemaccel complexes and their elimination from the bloodstream. This delay decreased when smaller volumes of Haemaccel were infused, which strongly suggests that plasma fibronectin is cleared by means of Haemaccel and does not seem to play a role of opsonin in these conditions.(ABSTRACT TRUNCATED AT 250 WORDS) [less ▲]

Detailed reference viewed: 49 (9 ULg)
Peer Reviewed
See detailInactivated Bovine Herpesvirus 1 Induces Apoptotic Cell Death of Mitogen-Stimulated Bovine Peripheral Blood Mononuclear Cells
Hanon, E.; Vanderplasschen, Alain ULg; Lyaku, S. et al

in Journal of Virology (1996), 70(6), 4116-4120

Bovine herpesvirus 1 (BHV-1) is able to inhibit the proliferation of bovine peripheral blood mononuclear cells. Here, we have demonstrated that live BHV-1 and, interestingly, inactivated BHV-1 can induce ... [more ▼]

Bovine herpesvirus 1 (BHV-1) is able to inhibit the proliferation of bovine peripheral blood mononuclear cells. Here, we have demonstrated that live BHV-1 and, interestingly, inactivated BHV-1 can induce apoptosis of mitogen-stimulated bovine peripheral blood mononuclear cells in vitro. [less ▲]

Detailed reference viewed: 7 (0 ULg)